Pharmabiz

Natera’s Signatera test receives Japan’ PMDA approval as a companion diagnostic in muscle-invasive bladder cancer

Natera’s Signatera test receives Japan’ PMDA approval as a companion diagnostic in muscle-invasive bladder cancer: Austin, Texas Friday, September 25, 2026, 17:00 Hrs [IST] Na ...
Pharmabiz

US FDA Advisory Committee recommends marketing approval of GRAIL’s Galleri multi-cancer early detection test

US FDA Advisory Committee recommends marketing approval of GRAIL’s Galleri multi-cancer early detection test: Sunnyvale, California Friday, September 25, 2026, 15:00 Hrs [IST] G ...
Pharmabiz

Gossamer Bio submits NDA to US FDA for seralutinib to treat pulmonary arterial hypertension

Gossamer Bio submits NDA to US FDA for seralutinib to treat pulmonary arterial hypertension: San Diego Friday, September 25, 2026, 16:00 Hrs [IST] Gossamer Bio, Inc., a clinical-s ...
Pharmabiz

Hikma Pharmaceuticals appoints Rebecca Hall as CFO and executive director

Hikma Pharmaceuticals appoints Rebecca Hall as CFO and executive director: London Friday, September 25, 2026, 18:00 Hrs [IST] Hikma Pharmaceuticals PLC (Hikma), a global pharma co ...
Pharmabiz

Astellas begins patient dosing in phase 3 study of setidegrasib in previously treated KRAS G12D- mutated advanced non-small cell lung cancer

Astellas begins patient dosing in phase 3 study of setidegrasib in previously treated KRAS G12D- mutated advanced non-small cell lung cancer: Tokyo Friday, September 25, 2026, 14: ...
Pharmabiz

UK MHRA grants marketing approval to Pharma Mar’s lurbinectedin for adults with extensive-stage small cell lung cancer

UK MHRA grants marketing approval to Pharma Mar’s lurbinectedin for adults with extensive-stage small cell lung cancer: United Kingdom Friday, September 25, 2026, 10:00 Hrs [IST ...
Pharmabiz

Honeywell report reveals gaps in industry’s OT cybersecurity protection despite rising AI-enabled critical infrastructure threats

Honeywell report reveals gaps in industry’s OT cybersecurity protection despite rising AI-enabled critical infrastructure threats: Our Bureau Bengaluru Friday, September 25, 202 ...
Pharmabiz

Arogya Manthan 2026 to launch new digital health and health assurance initiatives

Arogya Manthan 2026 to launch new digital health and health assurance initiatives: Our Bureau, Mumbai Friday, September 25, 2026, 15:45 Hrs [IST] Union minister for health and fam ...
Pharmabiz

NIH funded study shows modified HIV drug reverses vision loss and paralysis in multiple sclerosis model

NIH funded study shows modified HIV drug reverses vision loss and paralysis in multiple sclerosis model: Bethesda, Maryland Friday, September 25, 2026, 12:00 Hrs [IST] A new Natio ...
Pharmabiz

Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session

Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session: Cambridge, UK Friday, September 25, 2026, 11:00 Hrs [IST] Al ...
Pharmabiz

Xenix Medical’s Riva Anchor Spinopelvic fixation system receives US FDA 510(k) clearance with NanoACTIV surface technology

Xenix Medical’s Riva Anchor Spinopelvic fixation system receives US FDA 510(k) clearance with NanoACTIV surface technology: Orlando, Florida Friday, September 25, 2026, 13:00 Hr ...
Pharmabiz

Merck’s remigromig meets primary endpoint in the pivotal phase 2b/3 BRUNELLO study of adults with diabetic macular edema

Merck’s remigromig meets primary endpoint in the pivotal phase 2b/3 BRUNELLO study of adults with diabetic macular edema: Rahway, New Jersey Friday, September 25, 2026, 09:00 Hr ...